MX2011003749A - Sistema para suministrar medicamentos de liberacion sostenida. - Google Patents

Sistema para suministrar medicamentos de liberacion sostenida.

Info

Publication number
MX2011003749A
MX2011003749A MX2011003749A MX2011003749A MX2011003749A MX 2011003749 A MX2011003749 A MX 2011003749A MX 2011003749 A MX2011003749 A MX 2011003749A MX 2011003749 A MX2011003749 A MX 2011003749A MX 2011003749 A MX2011003749 A MX 2011003749A
Authority
MX
Mexico
Prior art keywords
active agent
chitosan
release
gastric juice
pharmaceutically
Prior art date
Application number
MX2011003749A
Other languages
English (en)
Inventor
Subheet Jain
Sumeet Dhaliwal
Madhu Rana
Pal Singh Hardevinder
A K Tiwary
Original Assignee
Bioplus Life Sciences Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioplus Life Sciences Pvt Ltd filed Critical Bioplus Life Sciences Pvt Ltd
Publication of MX2011003749A publication Critical patent/MX2011003749A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Abstract

La invención revela una forma de dosificación de liberación controlada que comprende una cantidad terapéuticamente efectiva de un agente farmacéuticamente activo, representado por Acyclovir, que liberaría en aproximadamente 12 horas no más de aproximadamente 90% de dicho agente activo en un jugo gástrico simulado a una velocidad de liberación de primer orden en una prueba de disolución tipo 1 de la USP, y sin contener un solubilizante o un reforzador del hinchamiento o ambos, que comprende (a) una tableta hecha de una matriz de polímero de por lo menos dos polímeros biocompatibles, representados por Carbopol 974P y óxido de polietileno, el agente farmacéuticamente activo y excipientes farmacéuticamente permitidos; la tableta es capaz de un hinchamiento rápido sin desintegración en el jugo gástrico simulado a un tamaño que conduciría a su retención gástrica en el estómago e iniciaría la liberación controlada de dicho agente activo al comenzar la erosión controlada así como la difusión inmediatamente después de entrar en contacto con dicho jugo gástrico; o (b) microesferas de quitosano no injertado o un derivado de quitosano representado por quitosano tiolado y trimetil quitosano, o Carbopol que se incorporan a dicho agente activo, donde dicho agente farmacéuticamente activo no es una molécula polimérica y después de la administración en el estómago, dichas moléculas se adhieren a la mucosa gástrica durante un tiempo prolongado liberando el agente activo en una forma controlada.
MX2011003749A 2008-10-08 2009-10-08 Sistema para suministrar medicamentos de liberacion sostenida. MX2011003749A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2158MU2008 2008-10-08
PCT/IN2009/000562 WO2010041279A2 (en) 2008-10-08 2009-10-08 Sustained release drug delivery system

Publications (1)

Publication Number Publication Date
MX2011003749A true MX2011003749A (es) 2011-09-01

Family

ID=42101042

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011003749A MX2011003749A (es) 2008-10-08 2009-10-08 Sistema para suministrar medicamentos de liberacion sostenida.

Country Status (14)

Country Link
US (2) US9622977B2 (es)
EP (1) EP2349221A4 (es)
JP (1) JP2012505203A (es)
KR (1) KR20110069150A (es)
CN (1) CN102307574A (es)
AP (1) AP2011005687A0 (es)
AU (1) AU2009301994B2 (es)
BR (1) BRPI0914080A2 (es)
CA (1) CA2739246A1 (es)
EA (1) EA201170529A1 (es)
IL (1) IL212195A0 (es)
MX (1) MX2011003749A (es)
WO (1) WO2010041279A2 (es)
ZA (1) ZA201103240B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2605655T3 (en) 2010-08-19 2019-02-04 Buck Institute For Age Res METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS
CN102784203A (zh) * 2011-05-20 2012-11-21 上海凯宝药业股份有限公司 一种痰热清片剂及其制备方法
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013123426A1 (en) * 2012-02-18 2013-08-22 Buck Institute For Research On Aging Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions
JP2016520653A (ja) * 2013-06-05 2016-07-14 シンクロニューロン インコーポレイテッド アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
ITUB20150279A1 (it) * 2015-03-09 2016-09-09 S I I T S R L Servizio Int Imballaggi Termosaldanti Sistema flottante per la cura dei sintomi delle affezioni gastriche
US10182993B2 (en) 2015-04-06 2019-01-22 Patheon Softgels Inc. Compositions for colonic delivery of drugs
CN105496982B (zh) * 2015-12-24 2018-10-19 广东药科大学 一种壳聚糖片剂及其制备方法
US20200383932A1 (en) * 2019-06-05 2020-12-10 The Florida International University Board Of Trustees Biotherapy for viral infections using biopolymer based micro/nanogels
CN111302859A (zh) * 2020-03-27 2020-06-19 王世伟 一种新型土壤改良剂的制备和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
ES2248908T7 (es) 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
WO1999007342A1 (en) 1997-08-11 1999-02-18 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
WO2001010405A1 (en) * 1999-08-04 2001-02-15 Ranbaxy Laboratories Limited Hydrodynamically balanced oral drug delivery system
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US20020119192A1 (en) * 2000-09-22 2002-08-29 Vishwanathan Narayanan Badri Controlled release formulations for oral administration
US20040219186A1 (en) * 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
AU2002302890A1 (en) * 2002-02-04 2003-12-02 Ranbaxy Laboratories Limited Hydrodynamically balancing oral drug delivery system with biphasic release
US6787234B2 (en) 2002-05-15 2004-09-07 Oms Investments, Inc. Triggered start products and processes for the production and use thereof
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
US20040016702A1 (en) 2002-07-26 2004-01-29 Applera Corporation Device and method for purification of nucleic acids
US20070196396A1 (en) * 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
JP2009500317A (ja) * 2005-06-29 2009-01-08 パナセア バイオテック リミテッド 放出特性改良医薬組成物およびその製造方法
JP4699896B2 (ja) 2005-12-28 2011-06-15 ジーイー・メディカル・システムズ・グローバル・テクノロジー・カンパニー・エルエルシー 超音波プローブ保護用ブラケット及び超音波プローブ
BRPI0705072B8 (pt) 2007-04-27 2021-05-25 Univ Estadual Campinas Unicamp grânulos mucoadesivos contendo nano e/ou microesferas de quitosana e processo de obtenção de grânulos mucoadesivos
ZA200903854B (en) 2008-06-19 2011-02-23 Univ Of The Witwatesrand Johannesburg A gastroretentive pharmaceutical dosage form

Also Published As

Publication number Publication date
US9622977B2 (en) 2017-04-18
AU2009301994A1 (en) 2010-04-15
ZA201103240B (en) 2011-12-28
US20170165269A1 (en) 2017-06-15
US20110244034A1 (en) 2011-10-06
BRPI0914080A2 (pt) 2015-10-27
JP2012505203A (ja) 2012-03-01
WO2010041279A4 (en) 2010-09-10
CN102307574A (zh) 2012-01-04
EP2349221A4 (en) 2013-03-27
AU2009301994B2 (en) 2016-10-20
EA201170529A1 (ru) 2012-01-30
AP2011005687A0 (en) 2011-06-30
IL212195A0 (en) 2011-06-30
WO2010041279A3 (en) 2010-07-01
CA2739246A1 (en) 2010-04-15
KR20110069150A (ko) 2011-06-22
WO2010041279A2 (en) 2010-04-15
EP2349221A2 (en) 2011-08-03

Similar Documents

Publication Publication Date Title
MX2011003749A (es) Sistema para suministrar medicamentos de liberacion sostenida.
AU2018200402B2 (en) Abuse-resistant mucoadhesive devices for delivery of buprenorphine
Debotton et al. Applications of polymers as pharmaceutical excipients in solid oral dosage forms
Bayrak et al. Formulation of zolmitriptan sublingual tablets prepared by direct compression with different polymers: In vitro and in vivo evaluation
JP5646340B2 (ja) ポリマー性対イオンと活性成分との塩
ES2200166T3 (es) Comprimido farmaceutico de liberacion controlada que contiene un soporte a base de amilosa reticulada e hidroxipropilmetilcelulosa.
US10548839B2 (en) Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
TW201929839A (zh) 一種控釋藥物組合物及其製備方法
IE61547B1 (en) Controlled release combination of carbidopa/levodopa
US20210308040A1 (en) Ketamine oral transmucosal delivery system
KR101156054B1 (ko) 안정한 에페리손 함유 서방성 의약조성물
US20160256392A1 (en) Abuse-deterrent dosage forms
JP2009534462A (ja) ニメスリドを含有する新規な低用量医薬組成物、その調製および使用
JP5694773B2 (ja) 圧縮成型製剤およびその製造方法
TWI612975B (zh) 速崩散性錠劑
CN101022808B (zh) 含有活性组分的胃滞留片剂的药物组合物
US20060159751A1 (en) Controlled release pharmaceutical compositions of carbidopa and levodopa
ES2693156T3 (es) Comprimido de liberación sostenida que contiene levodropropizina y método para prepararlo
Sharmin et al. Preparation and characterization of lidocaine double layer buccal tablet using mucoadhesive Carbopol® polymers
US20140377343A1 (en) Formulations of flurbiprofen and diacerein
Kumari et al. Formulation and Evaluation of Gastro Retentive Matrix Tablets of Sitagliptin
CN104188930A (zh) 一种阿西美辛三层控释片及其制备方法
Attuluri et al. Development and In Vitro evaluation of buccoadhesive tablets of losartan potassium
KR20090022612A (ko) 신규한 서방출형 아세클로페낙 제제 조성물 및 그의제조방법
Mogil Formulation and Evaluation of Extended Release Matrix Tablets of Trimetazidine Dihydrochloride.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal